

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



UNISOUND AI TECHNOLOGY CO., LTD.

雲知聲智能科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9678)

**VOLUNTARY ANNOUNCEMENT
IN RELATION TO THE INCREASE IN H SHAREHOLDING BY THE
CONTROLLING SHAREHOLDER, EXECUTIVE DIRECTOR AND
CHIEF EXECUTIVE OFFICER AND EXECUTIVE DIRECTOR**

This announcement is made by Unisound AI Technology Co., Ltd. (the “**Company**”) on a voluntary basis.

The board of directors of the Company (the “**Board**”) announces that it was informed by Dr. Huang Wei, the controlling shareholder, an executive Director and the chief executive officer of the Company, that he had purchased on the open market with his own funds during the period from July 6, 2026 to July 16, 2026 a total of 56,000 H Shares of the Company (the “**Dr. Huang Wei’s Shareholding Increase**”), with an aggregate consideration for increase amounting to HK\$3,979,255.90.

The Board was also informed by Dr. Liu Shengping, an executive Director of the Company, that he had purchased on the open market with his own funds during the period from July 7, 2026 to July 16, 2026 a total of 15,140 H Shares of the Company (the “**Dr. Liu Shengping’s Shareholding Increase**”), with an aggregate consideration for increase amounting to HK\$1,125,933.00.

Dr. Huang Wei’s Shareholding Increase and Dr. Liu Shengping’s Shareholding Increase are the personal actions of Dr. Huang Wei and Dr. Liu Shengping, demonstrating their confidence in the overall development prospects and growth potential of the Company. Dr. Huang Wei has also informed the Company that he plans to further increase his shareholding in the H Shares of the Company on the open market with his own funds in the future, based on market conditions and in accordance with applicable laws and regulations (the “**Planned Shareholding Increase**”). Dr. Huang Wei has confirmed that the Planned Shareholding Increase will be implemented in compliance with applicable laws, regulations and

regulatory requirements (including the Codes on Takeovers and Mergers and Share Buy-backs), and will ensure that the implementation and completion of the Planned Shareholding Increase will not trigger a mandatory general offer obligation under Rule 26 of the Codes on Takeovers and Mergers and Share Buy-backs on the part of Dr. Huang Wei himself, or the group of parties acting in concert comprising Dr. Huang Wei, Dr. Liang Jia'en and Dr. Kang Heng by virtue of their acting-in-concert arrangement.

As at the date of this announcement, the total number of issued shares of the Company was 74,675,593, comprising 24,995,061 Domestic Unlisted Shares, 4,570,649 Unlisted Foreign Shares and 45,109,883 H Shares.

Immediately after the Dr. Huang Wei's Shareholding Increase, Dr. Huang Wei directly held 56,000 H Shares and was deemed to be interested in 19,349,872 Shares (comprising 5,804,961 H Shares and 13,544,911 Domestic Unlisted Shares) through Yungsi Shangyi (Tianjin) Enterprise Management Partnership (Limited Partnership) (雲思尚義(天津)企業管理合夥企業(有限合夥)) ("Yungsi Shangyi") and Beijing Yunchuang Hudong Investment Management Consulting Partnership (Limited Partnership) (北京雲創互動投資管理諮詢合夥企業(有限合夥)) ("Yunchuang Hudong"), which are controlled by him. Accordingly, Dr. Huang Wei was interested in an aggregate of 19,405,872 Shares, representing approximately 25.99% of the total number of issued shares of the Company. Immediately following the Dr. Liu Shengping's Shareholding Increase, Dr. Liu Shengping directly held 15,140 H Shares, representing approximately 0.02% of the total number of issued shares of the Company.

To the best of the Company's knowledge and as confirmed by each of the controlling shareholders, since the Company's listing, none of the Company's controlling shareholders, namely Dr. Liang Jia'en, Dr. Huang Wei, Dr. Kang Heng, Tianjin Yunsheng Information Technology Co., Ltd. (天津市雲盛信息技術有限公司), Yungsi Shangyi and Yunchuang Hudong, have reduced their respective equity interests in the Company. Following the Dr. Huang Wei's Shareholding Increase, Dr. Huang Wei, Dr. Liang Jia'en and Dr. Kang Heng, by virtue of their acting-in-concert arrangement, were deemed to be interested in an aggregate of 23,601,661 Shares, comprising 16,481,964 Domestic Unlisted Shares and 7,119,697 H Shares, representing approximately 31.61% of the total number of issued shares of the Company.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Unisound AI Technology Co., Ltd.
Dr. Huang Wei
Executive Director and Chief Executive Officer

Beijing, the PRC
July 23, 2026

As at the date of this announcement, the Board of Directors of the Company comprises: (i) Dr. Liang Jia'en, Dr. Huang Wei, Dr. Kang Heng, Dr. Li Xiaohan and Dr. Liu Shengping as executive directors; and (ii) Mr. Hu Jianjun, Dr. Fan Jian, Dr. Jin Huihua and Dr. Zhang Kun as independent non-executive directors.